Results 171 to 180 of about 93,643 (259)

Predicting and Comparing the Subjective Health Experience of Older Cancer Survivors and Non‐Cancer Survivors: A Modeling Approach

Aging and Cancer, EarlyView.
This study underscores the significant influence of frailty and vitality on the subjective health experience of older cancer survivors with acceptance and control emerging as salient mediators. These findings affirm the conceptual and empirical robustness of the model highlighting its potential utility in shaping future interventions for older cancer ...
Damien S. E. Broekharst, Sjaak Bloem, Eline J. Mertens, Nathascha Hanzen, Michel van Agthoven   +4 more
wiley   +1 more source

Merging Pyrrole with Boron into Versatile Di(2-pyrryl)borane Building Blocks: π-Extension, Polymerization, and Coordination. [PDF]

Angew Chem Int Ed Engl
Göbel D, Helbig A, Friedrich A, Bachmann J, Buckel M, Chorbacher J, Helten H.   +6 more
europepmc   +1 more source

Cutaneous Melanoma Drives Metabolic Changes in the Aged Bone Marrow Immune Microenvironment

Aging and Cancer, EarlyView.
Melanoma, the deadliest form of skin cancer, increasingly affects older adults. Our study reveals that melanoma induces changes in iron and lipid levels in the bone marrow, impacting immune cell populations and increasing susceptibility to ferroptosis.
Alexis E. Carey, Murilo Ramos Rocha, Cheyenne Palm, Vania Wang, Denys Balandin, Ethan Black, Kevin Y. Zhang, Fan Huang, Daniel J. Zabransky, Yash Chhabra, Mareike Peters, Gabriel Ghiaur, Ashani Weeraratna   +12 more
wiley   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

The Ripple Effect: Applying Positive Psychology Principles in Debriefing to Transform Team Culture. [PDF]

Cureus
Kessler DO, Feingold J, Elkin R, Dube M, Reid J.   +4 more
europepmc   +1 more source

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

Ubuntu as a blueprint: learning ethical transdisciplinarity from African indigenous knowledge systems. [PDF]

Front Res Metr Anal
Gqaleni N, Foláyan MO.
europepmc   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

The Typability Index: A tool for measuring and controlling for typing difficulty in text stimuli. [PDF]

Behav Res Methods
Williams EA, Warburton M, Krzywinski M, Mushtaq F.   +3 more
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source